Can China's Biotechnology R & D revive its reputation in 2019?

Despite the rapid development of R & D in China in 2018, the world also pays attention to the scandals in the industry This year, it is worth mentioning that he Jiankui released the news in November that he edited the human embryo gene of the baby His gene editor suggested to provide HIV protection for the baby, but this serious violation of medical ethics caused the anger of the academic circles all over the world "In the gene editing baby incident, Chinese authorities apparently didn't make proper disclosure and there was serious regulatory oversight, which also led to the scandal continued to ferment and a strong international backlash," foreign media fierce biotech accused There is no doubt that this shocking experiment has damaged China's scientific reputation " In addition, this year, intellectual property theft involving GlaxoSmithKline and Genentech by Chinese researchers has been fermented, and a series of similar incidents have little help to China's position in biotechnology research and development Helen Chen, a Lek consulting firm, said: "this is a reputation issue Whether the actual situation improves or not, it may have a certain impact on related industries in China in the next few years Many companies are now actively involved in the biotechnology market Because it is difficult to recruit enough patients in the domestic market at a sufficient speed, more and more companies choose to see China as part of their global clinical plan, but the successive scandals may affect the trust of the industry " However, it should not be ignored that China's biotechnology companies have also made great progress this year, with a large amount of cash investment flowing into Chinese and American biotechnology companies There are also a lot of new progress reports on biotechnology and clinical pipeline One of the important factors is the new policy issued by the Hong Kong stock exchange, which allows companies to be listed for the first time, making it a hot spot in the global biotechnology IPO Geli bio, Baiji Shenzhou, Hualing pharmaceutical and Xinda bio pharmaceutical are among the first biotech companies to adopt this approach Currently, about 100 biotech companies are still queuing up to be listed for financing The Hong Kong Stock Exchange's move has indeed increased the recognition of Chinese biopharmaceutical companies by the outside world and financial investors Chen believes that this has also led some Western companies to reconsider their strategy in China, whether it is financing listing or product marketing At the same time, the Committee on foreign investment in the United States (CFIUS) held high the banner of protectionism on China's investment, saying that "the form advocated by the United States is a balance, and China's investment in US biotechnology is under review" There is no doubt that such unreasonable hegemony and trade protection policies have affected China's investment in US biotechnology For example, the segmentation of momenta's bio generic pharmaceutical business has attracted the interest of many Chinese buyers However, due to the interference of CFIUS administrative intervention and other factors, Chinese investors are unable to realize the investment operation in the end McKinsey also pointed out that although Chinese investment has already poured into the field of biotechnology in the United States, the trade tension between China and the United States caused by President trump of the United States may have a huge resistance to the benign biotechnology investment of the two countries in the future According to a recent McKinsey report, China's biotechnology regulatory environment is making great progress, which will help China consolidate its position in this field in 2019 and beyond The reform of China National Drug Administration (nmpa) is developing rapidly, the number of drug applications is increasing, and priority is given to the clinical urgently needed drugs, which will further improve the convenience of public access to drugs Faster review of clinical trial applications is also advancing, and according to the latest revision of the nmpa review process, if the agency does not reject a response within 60 working days after the application is submitted, the application will be approved In addition, another sign of China's biotechnology development can be seen from the migration of talents In particular, it has been seen that senior managers of many multinational pharmaceutical companies choose to move to China's emerging biotechnology companies For example, China's R & D directors of Lilly, Sanofi and Johnson & Johnson respectively moved to Cinda bio pharmaceutical, cornerstone pharmaceutical and Tianjing bio, and the president of Pfizer Greater China moved to Baiji Shenzhou A poll of senior executives from multinational companies also found that they believe "China still lacks high-quality talents to support sustainable biopharmaceutical innovation" McKinsey said that China is experiencing a serious talent shortage in this field, which is expected to continue in the next 2-3 years This also shows that China's biopharmaceutical innovation enterprises will still absorb a large number of high-quality talents in the future Relevant surveys show that accelerating review and approval, improving the reimbursement process of innovative therapies, increasing medical investment and stronger R & D capabilities all contribute to the strengthening of China's pharmaceutical industry However, compared with the United States, China still has a large gap For example, the uniqueness of innovative assets still lags behind the United States more, but with the overall growth of local innovation channels and more China There are clear signs in the company's listing permission plan that China's biotechnology innovation ecosystem is steadily improving The changing environment is partly due to the Chinese government's investment and encouragement in biotechnology over the past decade In recent years, enterprises and investors have finally benefited from this and achieved some practical results In some areas, China is likely to surpass the West in biotechnology research and development Industry observers believe that China is actively applying artificial intelligence to health care, in which China has become a strong competitor In general, China may continue to play the role of a fast follower for a long time to come The discussion on the value analysis of innovative drugs in the pharmaceutical and biological industry has not been over There is no clear answer for the best in the same category and the first in the same category However, for China's biotechnology industry, the best strategy seems to be a sustained, stable and rapid catch-up (compiled by Sina pharmaceutical / fan Dongdong, edited by / Kerr) article reference source: 1 Can China's R & D sector share its representative issues in 2019?